Original ArticleAccounting for Restart Rates in Evaluating Persistence with Ocular Hypotensives
Section snippets
Sample
Data were derived from a retrospective cohort analysis using a large national administrative medical care claims database with an annual enrollment of approximately 3 million members enrolled in commercial health maintenance organizations, preferred provider organizations, and Medicare risk plans. Patient and physician information was encrypted appropriately and qualifies as deidentified in accordance with the privacy regulations of the United States Department of Health and Human Services,
Results
In all, 4356 patients initiated treatment with an ocular prostaglandin. Patient demographic and ocular characteristics are summarized in Table 1. In brief, 74% of patients were older than 64 years, 58% were female, and 65% of those for whom a diagnosis was recorded had open-angle glaucoma.
Of the 4356 patients initially treated with a prostaglandin (Fig 1) and who met eligibility criteria for defining the index therapy, 2503 (57%) were eligible for final inclusion (were still plan members and
Discussion
Physicians need to monitor closely patients’ actual use of therapies to distinguish between a lack of clinical response to a medication taken as prescribed and a lack of persistence with the therapeutic regimen. Incomplete information concerning persistence may result in inappropriate changes in therapy. Current users include both those who persist in using the index agent and those who, after discontinuation, restart their index therapy. We have described a method of calculating current use
References (13)
- et al.
Patient persistency with topical ocular hypotensive therapy in a managed care population
Am J Ophthalmol
(2004) - et al.
Persistency with latanoprost or timolol in primary open-angle glaucoma suspects
Am J Ophthalmol
(2004) - et al.
Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study
Clin Ther
(2003) - et al.
Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size
Am J Ophthalmol
(2004) Compliance and persistance [in French]
J Fr Ophtalmol
(2006)- et al.
Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension
Can J Ophthalmol
(2005)
Cited by (38)
Big data and ophthalmic research
2016, Survey of OphthalmologyCitation Excerpt :Patient adherence and persistence with their glaucoma medication provides an insight into compliance and also the effectiveness and tolerability associated with a particular drug or class of drug. Reardon and colleague used health and pharmaceutical claims data from the Protocare Sciences managed care database to study over 28,000 patients aged over 20 years who were dispensed topical ocular hypotensives.203,211,212,229,231 They found that discontinuation rates were high: only 33% of those prescribed latanoprost were still using it after 12 months and continued use in other drug classes were even lower (19%).
Mirror-hat device as a drop delivery aid: A pilot study
2014, Canadian Journal of OphthalmologyCitation Excerpt :The most common reasons for not wanting to purchase it included fitting the hat properly (3), the mirror was too disorientating (2), too small a space between eye and mirror (1), the hat was difficult to use (3), problems using nondominant hand to put eye drops (4), vision too poor (2), and confidence with their current drop instillation technique (6). Many studies have reported poor eye-drop administration technique1–17 including contamination of the bottle tip in 25% to 80% of cases.1–3,10,11,13,15,17 Geyer et al.20 reported a 40% contamination rate 8 weeks or longer after opening a bottle, compared with a 19% contamination rate if bottles are used for less than 8 weeks.
Use of glaucoma medications: State of the science and directions for observational research
2010, American Journal of OphthalmologyCitation Excerpt :Overall, studies reported higher adherence or persistence, or both, with prostaglandin analogs, particularly latanoprost,30,35,36,38,40–42,53 compared with drugs such as β-blockers and carbonic anhydrase inhibitors.30,35,36,38–43,49,50,53 However, approximately half of patients discontinuing prostaglandin therapy failed to restart any other topical therapy.51 Four studies that compared adherence between different prostaglandin analogs28,33,37,52 found better adherence with latanoprost, but with a higher average cost per patient per year.28
Adherence and Persistence to Medical Therapy in Glaucoma: An Overview
2023, Ophthalmology and TherapyEvaluation of automatic monitoring of instillation adherence using eye dropper bottle sensor and deep learning in patients with glaucoma
2019, Translational Vision Science and Technology
Manuscript no. 2006-560.
This research was supported by Pfizer Inc.
The authors have no conflicting relationship with regard to the article’s content.